DAIC

JUNE 21, 2024

milla1cf Fri, 06/21/2024 - 20:10 June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using the Edwards EVOQUE system. by the Food and Drug Administration.

Tricuspid 105

Tricuspid Quality of Life Open-Heart Surgery Interventional Cardiology 105

DAIC

FEBRUARY 9, 2024

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. The first 100 minimally invasive tricuspid procedures were done as part of the TRISCEND II clinical trial. Image by Getty. Image by Getty. Food and Drug Administration (FDA).

Tricuspid 105

Tricuspid Open-Heart Surgery Interventional Cardiology Bicuspid/Mitral 105

DAIC

FEBRUARY 21, 2024

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. director of Interventional and Structural Heart Research at Henry Ford Hospital.

Heart Failure 105

Heart Failure Open-Heart Surgery Tricuspid Heart Disease 105

Cardiometabolic Health Congress

JULY 17, 2024

Join us as we examine the landmark approvals that are revolutionizing patient outcomes. Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Defibrillator 59